SAN FRANCISCO, April 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced several presentations at upcoming medical conferences that will feature its investigational drugs MDV3100 and Dimebon.
2009 American Urological Association (AUA) Annual Meeting, April 25-30, Chicago
61st American Academy of Neurology (AAN) Annual Meeting, April 25 - May 2, Seattle
MDV3100 is a novel small-molecule androgen receptor antagonist drug candidate in development for the treatment of castration-resistant (also known as hormone-refractory) prostate cancer (CRPC). MDV3100 has completed enrollment in a Phase 1-2 study and is expected to enter Phase 3 development this year in patients with CRPC who have failed docetaxel-based chemotherapy.
MDV3100 has a novel mechanism of action unlike that of the leading anti-androgen therapy used to treat CRPC. This mechanism potentially explains why MDV3100 has demonstrated beneficial effects in patients whose tumors are no longer responding to the currently available treatments for prostate cancer, including bicalutamide.
Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease (AD) and in clinical development for Huntington's disease (HD).
In preclinical models of AD and HD explored thus far, Dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The Dimebon mechanism is thought to be distinct from currently available AD medications.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.
This press release contains forward-looking statements, including statements regarding the timing of Phase 3 trials, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 16, 2009. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
|SOURCE Medivation, Inc.|
Copyright©2009 PR Newswire.
All rights reserved